- Dubai Debt Delay Rattles Stock, Bond Markets
- Fannie Mae to Tighten Lending Standards: Report
- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Wal-Mart Price Pressure Hurts China Workers: Report
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Where Do Pardoned Turkeys Go?
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- London stock trading to resume after outage
- Japan's Kyodo forms tie-up with Mainichi newspaper
- Nokia Siemens to manage Zain networks in E.Africa
- BAE plans to ax a further 640 jobs
- China Minsheng bank IPO slides 3 pct in HK debut
- EU charges Philips, others with price-fixing
- Energy agency head praises Obama emissions goal
- Taiwan economy shrinks at slower pace in 3Q
- Malaysia plans 4 percent sales tax by 2011
Text Size 
WASHINGTON - The Food and Drug Administration says Advair, a widely used asthma drug, does not appear to have an increased risk of serious complications seen with some newer medicines.
The agency analyzed reams of clinical data on four drugs: Advair, Foradil, Serevent, and Symbicort. All carry strong warnings already, but the findings could lead to more specific instructions for patients.
The FDA is concerned about asthma drugs known as LABAs, long-acting medications that relax tight muscles around stressed airways. LABAs can increase risks of death and complications in some patients. But the risk is less when LABAs are used together with a steroid to treat underlying inflammation inside airways. Advair combines both kinds of medicine in an inhaler.
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
- How can you get out of debt and back on the road to recovery? Follow these ten steps.
Data is a real-time snapshot *Data is delayed at least 15 minutes